AGENUS INC
AGENNext catalyst
Botensilimab
Metastatic Pancreatic Ductal Adenocarcinoma
Get an email about AGEN's next catalysts
Track AGENUS (AGEN) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 4 more upcoming events in our data (Phase 2 readout).See the timeline
5 upcoming, 1 past
Botensilimab Phase 2 Est. Readout
Estimated primary completion for Botensilimab trial (NCT06300463) in Colorectal Cancer Metastatic. Topline data typically follows completion by weeks to months.
SourceBalstilimab Phase 2 Est. Readout
Estimated primary completion for Balstilimab trial (NCT04028063) in Metastatic Soft Tissue Sarcoma. Topline data typically follows completion by weeks to months.
SourceBotensilimab Phase 2 Est. Readout (RECTIFY-1)
Estimated primary completion for Botensilimab trial (NCT07735624) in Early Rectal Cancer. Topline data typically follows completion by weeks to months.
SourceBotensilimab Phase 2 Est. Readout
Primary completion for Botensilimab trial (NCT05608044) in Metastatic Colorectal Cancer
SourceEvofosfamide Phase 2 Est. Readout
Estimated primary completion for Evofosfamide trial (NCT06782555) in Metastatic Prostate Cancer. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants designed for use with various vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients.
WebsiteFolfox Protocol
Gastric Cancer
Balstilimab
Advanced Melanoma
FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel)
Resectable MMR-deficient Solid Tumors
autologous human tumor-derived HSPPC-96
Renal Cell Carcinoma
HSPPC-96 or Oncophage
Malignant Melanoma
Botensilimab
Metastatic Pancreatic Ductal Adenocarcinoma
HSPPC-96
Non-Small-Cell Lung Carcinoma
AGEN2373
Pancreatic Cancer
CR6086
Refractory Metastatic Colorectal Cancer
NLM-001
Pancreatic Ductal Adenocarcinoma
Botensilimab + Balstilimab
Non-small Cell Lung Cancer
Evofosfamide
Metastatic Prostate Cancer
AGEN1423
Advanced Pancreatic Ductal Adenocarcinoma
Balstilmab
Anatomic Stage IV Breast Cancer AJCC v8
mKRASvax
Pancreatic Cancer
AGEN2373 (RP2D)
Pancreatic Cancer
GVAX
Pancreatic Cancer
AGEN2034
Advanced Cancer
AGEN1884
Cervical Cancer
AGEN1884 + AGEN2034
Cervical Cancer
Zalifrelimab
Advanced Solid Cancers
HerpV and QS-21
Herpes Simplex Type 2
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Folfox Protocol | Phase 3 | Gastric Cancer | - | - |
Balstilimab | Phase 3 | Advanced Melanoma | - | - |
FLOT (Fluorouracil+Leucovorin+Oxaliplatin+Docetaxel) | Phase 3 | Resectable MMR-deficient Solid Tumors | - | - |
autologous human tumor-derived HSPPC-96 | Phase 3 | Renal Cell Carcinoma | - | - |
HSPPC-96 or Oncophage | Phase 3 | Malignant Melanoma | - | - |
Botensilimab | Phase 3 | Metastatic Pancreatic Ductal Adenocarcinoma | - | - |
HSPPC-96 | Phase 2 | Non-Small-Cell Lung Carcinoma | - | - |
AGEN2373 | Phase 2 | Pancreatic Cancer | - | - |
CR6086 | Phase 2 | Refractory Metastatic Colorectal Cancer | - | - |
NLM-001 | Phase 2 | Pancreatic Ductal Adenocarcinoma | - | - |
Botensilimab + Balstilimab | Phase 2 | Non-small Cell Lung Cancer | - | - |
Evofosfamide | Phase 2 | Metastatic Prostate Cancer | - | - |
AGEN1423 | Phase 2 | Advanced Pancreatic Ductal Adenocarcinoma | - | - |
Balstilmab | Phase 2 | Anatomic Stage IV Breast Cancer AJCC v8 | - | - |
mKRASvax | Phase 2 | Pancreatic Cancer | - | - |
AGEN2373 (RP2D) | Phase 2 | Pancreatic Cancer | - | - |
GVAX | Phase 2 | Pancreatic Cancer | - | - |
AGEN2034 | Phase 2 | Advanced Cancer | - | - |
AGEN1884 | Phase 2 | Cervical Cancer | - | - |
AGEN1884 + AGEN2034 | Phase 2 | Cervical Cancer | - | - |
Zalifrelimab | Phase 2 | Advanced Solid Cancers | - | - |
HerpV and QS-21 | Phase 2 | Herpes Simplex Type 2 | - | - |
Frequently asked questions
What is in AGENUS INC's drug pipeline?→
CatalystAlert tracks 22 drug candidates in AGENUS INC's (AGEN) pipeline across Phase 3, Phase 2. Its lead program is Botensilimab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is AGENUS INC's next FDA catalyst?→
AGENUS INC's (AGEN) next tracked catalyst is a Phase 2 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AGEN biotech catalysts?→
Add AGEN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow AGENUS INC's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.